Jordi Remon, Tina Cascone, Stephanie P L Saw, Nikolaj Frost, Molly S C Li, Lizza E L Hendriks, Antonin Levy, Alessandro Di Federico, Jamie E Chaft, Karim Abdelhamid, Mark Awad, Giannis Mountzios, Solange Peters
The treatment of early-stage non-small-cell lung cancer (NSCLC) has evolved substantially in recent years. For decades, curative-intent surgery followed by platinum-based chemotherapy remained the standard of care (SOC), despite delivering only modest gains in long-term survival. Current evidence from randomised trials incorporating immunotherapy as a neoadjuvant or perioperative approach, along with targeted therapies, have defined a new SOC treatment approach for patients with resectable early-stage NSCLC. However, these advances have introduced uncertainties regarding optimal sequencing, treatment duration, patient selection, and the role of treatment escalation or de-intensification with immunotherapy and targeted therapies. The advances and uncertainties are discussed in this Series paper, along with the role of radiotherapy in this setting.